Takeaway

• In patients with metastatic colorectal cancer (mCRC) that is stable or responding after induction treatment, maintenance capecitabine almost doubles PFS, with no significant OS benefits.
• Data support the use of treatment breaks for these patients.
• Capecitabine is a reasonable option to discuss with patients.

Why this matters

• A maintenance...